Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Cross-reactivity00:42

Cross-reactivity

Overview
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Structure and Classes01:25

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

COLORFUL ENGINEERING.

BioTechniques·2017
Same author

FIGHTING FOR THE FUTURE OF ANTIBODIES.

BioTechniques·2017
Same author

STORIES IN ANCIENT DNA.

BioTechniques·2017
Same author

GOING WITH THE FLOW.

BioTechniques·2017
Same author

PCR'S NEXT WAVE.

BioTechniques·2017
Same author

CRISPR: MODIFYING THE LIFE SCIENCE LANDSCAPE.

BioTechniques·2016

関連する実験動画

Updated: Jul 14, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

アンチボディ: 世代ゲーム

Nathan Blow

    Nature
    |June 8, 2007
    PubMed
    まとめ

    高品質の抗体は,プロテオミクス研究にとって極めて重要です. 科学者は,信頼性の高い抗体を生成し,実験の精度とデータの検証を改善するための革新的な方法を模索しています.

    科学分野:

    • バイオケミストリー バイオケミストリー
    • 分子生物学は分子生物学である.
    • 免疫学 免疫学とは

    背景:

    • プロテオミクスは,タンパク質の正確な検出と定量化のために,特定の,検証された抗体に大きく依存しています.
    • よく特徴づけられた抗体の存在は,プロテオミクス研究を進める上で重要な瓶頸です.
    • 現在の抗体生成方法は,特異性と再現性を確保する上で課題に直面しています.

    研究 の 目的:

    • プロテオミクスのアプリケーションのための抗体生成戦略の現在の状況を見直す.
    • 高品質で検証された抗体を作るための新興技術とアプローチを強調する.
    • プロテオミクス研究における再定義された抗体生成の影響を議論する.

    主な方法:

    • 抗体生成技術に関する文献レビュー.
    • 抗体生産における新興技術の分析.
    • プロテオミクスにおける抗体生成方法の再定義に関するケーススタディ.

    主要な成果:

    • 伝統的な抗体検証における限界を特定する.
    • 抗体開発のための新しいプラットフォームの探索,再結合抗体生産およびin vitro選択を含む.

    さらに関連する動画

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology
    09:42

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology

    Published on: January 2, 2017

    Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
    13:14

    Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

    Published on: February 6, 2018

    関連する実験動画

    Last Updated: Jul 14, 2026

    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
    10:32

    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

    Published on: June 5, 2015

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology
    09:42

    Generation of Murine Monoclonal Antibodies by Hybridoma Technology

    Published on: January 2, 2017

    Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
    13:14

    Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

    Published on: February 6, 2018

  • 厳格な検証と特徴付けプロトコルの重要性を強調する.

    • 結論:

    • 革新的な抗体生成戦略は,現代のプロテオミクスの要求を満たすのに不可欠です.
    • 再定義されたアプローチは,タンパク質研究における抗体特異性,再現性,および全体的なデータ品質を向上させることを約束しています.
    • プロテオミクスの未来は,より優れた抗体反応剤の開発にますます依存しています.